 |
Vol.39 No.7 contents | Japanese/English |
- Original Article -
Clinical Significance of Serum Soluble Fas Antigen in Patients with Primary Lung Cancer
Shun Xu1,2 and Satoru Kobayashi11Department of Cardiothoracic Surgery, Dokkyo University School of Medicine, 2Department of Thoracic Surgery, 1st Affilitated Hospital, China Medical University
Objective: We evaluated the clinical siginificance of serum soluble Fas antigen (sFas) in patients with untreated primary lung cancer. Methods: Forty-five cases of untreaed primary lung cancer, including 22 squamous cell carcinomas, 17 adenocarcinomas, 6 small cell carcinomas and 15 healthy controls were studied. Serum samples were obtained. The sandwich method with an sFas kit reagent (MBL Company, Nagoya, Japan) was used. Results: Compared with healthy controls, the levels of serum sFas in all cases of lung cancer were increased siginificantly in each pathological type and in each stage of lung cancer. In stage IV, sFas was siginificantly higher than in all other stages. Conclusion: Serum sFas was increased in primary lung cancer. Its elevation may be related with the situation of carcinoma. In stage IV, sFas was siginificantly higher than other stages.
key words: Lung cancer, Soluble Fas antigen (sFas), Apoptosis
Received: July 14, 1999
Accepted: October 1, 1999
JJLC 39 (7): 969-974, 1999
